Background/Aims Hepatitis B virus reactivation (HBVr) following chemotherapy (CMT) is well-known among hematologic malignancies, and screening recommendations are established. However, HBVr data in solid organ malignancy (SOM) patients are limited. This study aims to determine hepatitis B surface antigen (HBsAg) screening rates, HBV prevalence, and the rate of significant hepatitis caused by HBVr in SOM patients undergoing CMT.
Methods Based on the Oncology unit’s registration database from 2009–2013, we retrospectively reviewed records of all SOM patients ≥18 years undergoing CMT at Songklanagarind Hospital who were followed until death or ≥6 months after CMT sessions. Exclusion criteria included patients without baseline liver function tests (LFTs) and who underwent CMT before the study period. We obtained and analyzed baseline clinical characteristics, HBsAg screening, and LFT data during follow-up.
Results Of 3,231 cases in the database, 810 were eligible. The overall HBsAg screening rate in the 5-year period was 27.7%. Screening rates were low from 2009–2012 (7.8–21%) and increased in 2013 to 82.9%. The prevalence of HBV among screened patients was 7.1%. Of those, 75% underwent prophylactic antiviral therapy. During the 6-month follow-up period, there were three cases of significant hepatitis caused by HBVr (4.2% of all significant hepatitis cases); all were in the unscreened group.
Conclusions The prevalence of HBV in SOM patients undergoing CMT in our study was similar to the estimated prevalence in general Thai population, but the screening rate was quite low. Cases of HBVr causing significant hepatitis occurred in the unscreened group; therefore, HBV screening and treatment in SOM patients should be considered in HBV-endemic areas.
Citations
Citations to this article as recorded by
Hepatitis B Virus Screening Prior to Chemotherapy in Patients with Solid Organ Malignancy at the Brazzaville University Hospital Pérès Mardochée Motoula Latou, Evodie Syntyche Motoula Latou, Alexis Fortuné Bolenga Liboko, Eliane Ndounga, Judith Nsonde Malanda, Blaise Irénée Atipo Ibara Open Journal of Gastroenterology.2025; 15(07): 390. CrossRef
Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysis Soe Thiha Maung, Natee Deepan, Pakanat Decharatanachart, Roongruedee Chaiteerakij Asia-Pacific Journal of Clinical Oncology.2024; 20(3): 335. CrossRef
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis Natee Deepan, Soe Thiha Maung, Pakanat Decharatanachart, Roongruedee Chaiteerakij Seminars in Oncology.2024;[Epub] CrossRef
Viral hepatitis B in patients with hematological malignancies (Overview) Sidorkevich SV, Chebotkevich VN, Kuleshova AV, Kajtandzhan EI, Bessmeltsev SS Archives of Hepatitis Research.2023; 9(1): 001. CrossRef
Systematic review of seroprevalence of markers of hepatitis B, C and HIV among oncohematological patients A.V. Satsuk, G.G. Solopova, A.A. Ploskireva, V.G. Akimkin Clinical Microbiology and Antimicrobial Chemotherapy.2023; 25(2): 131. CrossRef
Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin James Crosby, Forrest Smith, Subramanya Shyam Ganti, Nagabhishek Moka, Samuel Bailey Journal of Investigative Medicine High Impact Case Reports.2022;[Epub] CrossRef
HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program Supinya Sono, Jirayu Sae-Chan, Apichat Kaewdech, Naichaya Chamroonkul, Pimsiri Sripongpun, Jason T. Blackard PLOS ONE.2022; 17(6): e0270458. CrossRef
First
Prev
